Form 425 - Prospectuses and communications, business combinations
2024年8月7日 - 10:08PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): August 5, 2024
Hepion
Pharmaceuticals, Inc.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-36856 |
|
46-2783806 |
(State
or other jurisdiction |
|
(Commission |
|
IRS
Employer |
of
incorporation or organization) |
|
File
Number) |
|
Identification
No.) |
399
Thornall Street, First
Floor Edison,
NJ 08837
(Address
of principal executive offices)
Registrant’s
telephone number, including area code: (732) 902-4000
(Former
name or former address, if changed since last report)
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class: |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered: |
Common
Stock |
|
HEPA |
|
Nasdaq
Capital Market |
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
|
☒ |
Written communication pursuant to Rule 425 under the Securities
Act (17 CFR 230.425) |
|
|
|
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth
company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item
5.02 | Departure
of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. |
On
August 5, 2024, John Cavan, the interim Chief Executive Officer and Chief Financial Officer of Hepion Pharmaceuticals, Inc. (the “Company”)
left the Company for personal reasons. On August 6, 2024, John Brancaccio, the Company’s executive chairman was appointed the interim
Chief Executive Officer and interim Chief Financial Officer of the Company.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Dated:
August 7, 2024
|
|
HEPION
PHARMACEUTICALS, INC. |
|
|
|
|
|
By: |
/s/
John Brancaccio |
|
|
|
John
Brancaccio |
|
|
|
Interim
Chief Executive Officer and Interim Chief |
|
|
|
Financial Officer |
Hepion Pharmaceuticals (NASDAQ:HEPA)
過去 株価チャート
から 11 2024 まで 12 2024
Hepion Pharmaceuticals (NASDAQ:HEPA)
過去 株価チャート
から 12 2023 まで 12 2024